CXCL10 and myeloid sarcoma: Altogether, these clinical assays for IP10 and NF-\documentclass[12pt]{minimal}\usepackage{amsmath}\usepackage{wasysym}\usepackage{amsfonts}\usepackage{amssymb}\usepackage{amsbsy}\usepackage{mathrsfs}\usepackage{upgreek}\setlength{\oddsidemargin}{-69pt}\begin{document}$$\kappa$$\end{document}κB pathway inhibitors strengthen the potential of the pair as MS targets, where their simultaneous inhibition lowers the risk for MS.